The QUIBUS study is the largest investigation ever performed in Italy with an extensive use of the ICS-BPH questionnaire. The internal consistency of each of its three domains was high for ICS-Male (Cronbach’s alpha = 0.83 and 0.89 for symptoms and bother, respectively) and lower for ICS-Sex (Cronbach’s alpha = 0.63 and 0.75, see a following paper of this issue) and ICS-QoL (Cronbach’s alpha = 0.53), as previously reported in the validation study of this tool. Voiding symptoms were more frequently reported, with reduced urinary stream, terminal dribble and incomplete bladder emptying as the most frequently represented. The first storage symptom in the ranking by frequency was ‘rush to toilet’ (70% of the population), in 7th position; however, the relevant bother was among the highest reported. Items related to urinary incontinence appeared, when present, highly bothersome (87–92% of patients), even though exhibited by a minority of the population (5–34%). The mean (±SD) IPSS, calculated on 970 patients, was 15 (±7). Two major discrepancies were found in the comparison between IPSS and ICS-Male. First, terminal dribble, which is not considered in the IPSS, is often reported in the ICS-Male. Second, some storage symptoms (nocturia and day-time frequency) are less frequently reported in the ICS-Male than in the IPSS, while being, in general, highly bothersome. As regards QoL, 95% of subjects declared that they would not be completely happy to spend the rest of their life with their actual symptoms (ICS-QoL item 33) and 79% that BPH influences their life from ‘a little’ to ‘a lot’ (ICS-QoL item 30). The mean (±SD) IPSS-QoL single question score was 3.0 ± 1.4 (n = 970), and the frequency distribution of scores was equivalent to the one detected by the corresponding question of ICS-QoL (item 33). SF-36, a disease-independent questionnaire about QoL, after a 1-year follow-up is expected to clarify which among the IPSS and ICS-BPH items better describe the impact of BPH on QoL.

Keywords:
Epidemiology, Benign prostatic hyperplasia, Lower urinary tract symptoms, IPSS, ICS-BPH, Quality of life
1.
Boyle P, Maisonneuve P, Steg A: Decrease in mortality from benign prostatic hyperplasia: a major unheralded health triumph. J Urol 1996;155:176–180.
2.
Teillac P: Relief of BPO or improvement in quality of life? Eur Urol 1998;34:3–9.
3.
Abrams P, Donovan JL, de la Rosette JJ, Schafer W: International Continence Society ‘Benign Prostatic Hyperplasia’ Study: Background, aims, and methodology. Neurourol Urodyn 1997;16:79–91.
4.
Barry MJ, Fowler FJ Jr, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT: The American urological association symptom index for benign prostatic hyperplasia. J Urol 1992;148:1549–1557.
5.
Donovan JL, Abrams P, Peters TJ, Kay HE, Reynard J, Chapples C, De La Rosette JJMCH, Kondo A: The ICS-‘BPH’ study: The psychometric validity and reliability of the ICSmale questionnaire. Br J Urol 1996;77:554–562.
6.
Jolleys JV, Donovan JL, Nanchahal K, Peters TJ, Abrams P: Urinary symptoms in the community: how bothersome are they ? Br J Urol 1994;74:551–555.
7.
Donovan JL, Kay HE, Peters P, Abrams P, Coast J, Matos-Ferreira A, Rentzhog L, Bosch JLHR, Nordling, J, Gajewski JB, Barbalia G, Schick E, Mendes Silva M, Nissenkorn I, De La Rosette JJMCH: Using the ICSQoL to measure the impact of lower urinary tract symptoms on quality of life: Evidence from the ICS-‘BPH’ study. Br J Urol 1997;80:712–721.
8.
Rhodes PR, Krogh RH, Bruskewitz RC: Impact of drug therapy on benign prostatic hyperplasia-specific quality of life. Urology 1999;53:1090–1098.
9.
Witjes WPJ, Jean J, De La Rosette JMCH, Donovan JL, Peters TJ, Abrams P, Kay HE, Hofner K, Kinn AC, Walter S: The International Continence Society ‘Benign Prostatic Hyperplasia’ Study: International differences in lower urinary tract symptoms and related bother. J Urol 1997;157:1295–1300.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.